Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Cash & Equivalents (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Cash & Equivalents data on record, last reported at $29.6 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 24.45% year-over-year to $29.6 million; the TTM value through Sep 2025 reached $29.6 million, down 24.45%, while the annual FY2024 figure was $41.9 million, 7.27% down from the prior year.
  • Cash & Equivalents reached $29.6 million in Q3 2025 per SGMO's latest filing, down from $38.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $178.9 million in Q4 2021 and bottomed at $25.2 million in Q1 2025.
  • Average Cash & Equivalents over 5 years is $83.4 million, with a median of $66.8 million recorded in 2023.
  • The widest YoY moves for Cash & Equivalents: up 43.41% in 2021, down 63.66% in 2021.
  • A 5-year view of Cash & Equivalents shows it stood at $178.9 million in 2021, then crashed by 43.85% to $100.4 million in 2022, then plummeted by 55.0% to $45.2 million in 2023, then decreased by 7.27% to $41.9 million in 2024, then fell by 29.35% to $29.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $29.6 million in Q3 2025, $38.3 million in Q2 2025, and $25.2 million in Q1 2025.